The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease
JoAnn E. Manson(Brigham and Women's Hospital), Julie E. Buring(Brigham and Women's Hospital), Shumin M. Zhang(Tufts University), I‐Min Lee(Brigham and Women's Hospital), Jean MacFadyen(Brigham and Women's Hospital), Shari S. Bassuk(Cosmos Corporation (United States)), Nancy R. Cook(Brigham and Women's Hospital), David Gordon(NYU Langone Health), Michelle A. Albert(Brigham and Women's Hospital), Jennifer Lin(Brigham and Women's Hospital), Elaine Zaharris(Brigham and Women's Hospital)
Cited by 553
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
|The Journal of Clinical Endocrinology & Metabolism|2010|4k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Atherosclerosis
|Nature Reviews Disease Primers|2019|3k